EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia

Kana Kusaba, Tatsuro Watanabe, Keisuke Kidoguchi, Yuta Yamamoto, Ayaka Tomoda, Toshimi Hoshiko, Naoto Kojima iD, Susumu Nakata, Shinya Kimura

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252011093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kana Kusaba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japa…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Imatinib Mesylate, Oxidative Phosphorylation, Neoplastic Stem Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers-Squibb, Pfizer, Ohara Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with chronic myeloid leukemia (CML) respond to tyrosine kinase inhibitors (TKIs); however, CML leukemic stem cells (LSCs) exhibit BCR::ABL kinase-independent growth and are insensitive to TKIs, leading to disease relapse. To prevent this, new therapies targeting CML-LSCs are needed. Rates of mitochondria-mediated oxidative phosphorylation (OXPHOS) in CD34+CML cells within the primitive CML cell population are higher than those in normal undifferentiated hematopoietic cells; therefore, the inhibition of OXPHOS in CML-LSCs may be a potential cure for CML. NK-128 (C33H61NO5S) is a structurally simplified analog of JCI-20679, the design of which was based on annonaceous acetogenins. NK-128 exhibits antitumor activity against glioblastoma and human colon cancer cells by inhibiting OXPHOS and activating AMP-activated protein kinase (AMPK). Here, we demonstrate that NK-128 effectively suppresses the growth of CML cell lines and that the combination of imatinib and NK-128 is more potent than either alone in a CML xenograft mouse model. We also found that NK-128 inhibits colony formation by CD34+ CML cells isolated from the bone marrow of untreated CML patients. Taken together, these findings suggest that targeting OXPHOS is a beneficial approach to eliminating CML-LSCs, and may improve the treatment of CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveImatinib MesylateOxidative PhosphorylationNeoplastic Stem CellsHumansAnimalsMiceCell Line, TumorThiophenesXenograft Model Antitumor AssaysAntineoplastic AgentsCell ProliferationDrug SynergismProtein Kinase Inhibitors

Stichwörter der Autor:innen

chronic myeloid leukemiaoxidative phosphorylationstem cellthiophene carboxamidetyrosine kinase

Substanzen

Imatinib MesylateThiophenesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
  • Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
  • Clinical Research Center, Saga Medical School Hospital, Saga 849-8501, Japan.
  • Faculty of Pharmaceutical Sciences, Nagasaki International University, Nagasaki 859-3298, Japan.
  • Laboratory of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.

ORCID-Profile: Naoto Kojima

Förderung

  • Bristol-Myers-Squibb
  • Pfizer
  • Ohara Pharmaceuticals

Zitieren

APA

Kusaba, K., Watanabe, T., Kidoguchi, K., Yamamoto, Y., Tomoda, A., Hoshiko, T., Kojima, N., Nakata, S., & Kimura, S. (2024). Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252011093

Vancouver

Kusaba K, Watanabe T, Kidoguchi K, Yamamoto Y, Tomoda A, Hoshiko T, et al. Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252011093

BibTeX
@article{Kusaba2024,
  author = {Kusaba, Kana and Watanabe, Tatsuro and Kidoguchi, Keisuke and Yamamoto, Yuta and Tomoda, Ayaka and Hoshiko, Toshimi and Kojima, Naoto and Nakata, Susumu and Kimura, Shinya},
  title = {Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252011093}
}
Kostenlos starten →